Ethylene-vinyl alcohol copolymer-based non-adhesive liquid embolic agent for transcatheter arterial embolization in patients with abdominal/pelvic arterial bleeding: A prospective, single-arm, multicenter cohort study.

Fiche publication

Date publication

février 2025

Journal

Diagnostic and interventional imaging

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LOFFROY Romaric

Tous les auteurs :
Loffroy R, Kobeiter H, Vidal V, Frandon J, Pellerin O, Dean C, Sammoud S, Vernhet-Kovacsik H, Derbel H, Aho-Glélé LS, Chevallier O, Sapoval M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39952827

Résumé

The purpose of this study was to evaluate the safety and efficacy of a novel ethylene-vinyl alcohol copolymer-based non-adhesive liquid embolic agent for transcatheter arterial embolization (TAE) in patients with bleeding from abdominal and/or pelvic arteries MATERIALS AND METHODS: A prospective observational multicenter study (Clinicaltrials.gov Identifier: NCT04787120) included consecutive patients treated with TAE using a novel ethylene-vinyl alcohol copolymer-based non-adhesive liquid embolic agent (SQUID 18) at four university hospitals from 2021 to 2023. The indication for TAE included acute symptomatic bleeding or imminent risk of bleeding from visceral (n = 63), muscular (n = 23), or gastrointestinal (n = 29) abdominal/pelvic arteries combined with angiographic abnormalities. Patient characteristics, clinical success rates, and interventional-radiologist satisfaction with each TAE were assessed. Clinical success at 1- and 6 months was defined as survival without reintervention for rebleeding from the initially embolized site(s). Univariable and multivariable analyses were performed to identify variables associated with clinical failure of TAE.